作者: Dhillon, Jasvir ; Gizynski, Krzysztof ; Boada, Eduardo ; Adams, Candice ; Murton, Heather ; O'Halloran, Jonathan ; Butcher, Philip D ; Shabestary, Shireen ; McGurk, David ; Moore, Catherine M ; Flynn, Rebecca ; Morgan, George ; Peat, Jonathan ; Stoker, Neil G

To achieve the global efforts to end tuberculosis, affordable diagnostics suitable for true point-of-care implementation are required to reach the missing millions. In addition, diagnostics with increased sensitivity and expanded drug susceptibility testing are needed to address drug resistance and to diagnose low-bacterial burden cases. The laboratory-on-a-chip technology described herein used dielectrophoresis to selectively isolate Mycobacterium tuberculosis from sputum samples, purifying the bacterial population ahead of molecular confirmation by multiplex real-time quantitative PCR. After optimization using a panel of 50 characterized sputum samples, the performance of the prototype was assessed against the current gold standards, screening 100 blinded sputum samples using characterized and biobanked sputum provided by Foundation for Innovative New Diagnostics. Concordance with culture diagnosis was 100% for smear-negative samples and 87% for smear-positive samples. Of the smear-positive samples, the high burden sample concordance was 100%. Samples were diagnosed on the basis of visual assessment of the dielectrophoresis array and by multiplex real-time quantitative PCR assay. The results described herein demonstrate the potential of the CAPTURE-XT technology to provide a powerful sample preparation tool that could function as a front-end platform for molecular detection. This versatile tool could equally be applied as a visual detection diagnostic, potentially associated with bacterial identification for low-cost screening or coupled with an expanded PCR assay for genotypic drug susceptibility testing.

2021-06-01·European journal of human genetics : EJHG2区 · 生物学

The rise of point-of-care genetics: how the SARS-CoV-2 pandemic will accelerate adoption of genetic testing in the acute setting

2区 · 生物学

Article

作者: Burn, John ; Donnai, Dian ; McDermott, John H ; Newman, William G

The SARS-CoV-2 outbreak has necessitated innovation in many areas, including the development of mol. point-of-care tests (POCTs) to facilitate rapid diagnosis.Academia and industry have collaborated to produce these diagnostics at an unparalleled pace, drawing on various methodol. approaches.We make the case that the clin. genetics community is well-placed, given its unique history, to play a central role in the development and implementation of any new testing model.Traditionally, clin. genetics services have been gate-keepers to genetic testing.The current POCT revolution may well change that.We believe that our community has a critical role to play in shaping this revolution and we must not be bystanders.By collaborating with industry to develop robust diagnostics and working along side clinicians to integrate these tools into clin. pathways, we can help straddle the clin. - academic divide.The history of our specialty is, to a great extent, the history of mol. diagnostics.The rise of the genetic POCT is the next chapter in that story and we must adapt once more.

2017-01-01·Biosensors & bioelectronics

Metal-coated microfluidic channels: An approach to eliminate streaming potential effects in nano biosensors

Article

作者: Mu, Luye ; Lee, Jieun ; Adams, Chris ; Hannant, Jennifer ; Reed, Mark A ; Wipf, Mathias

We report a method to suppress streaming potential using an Ag-coated microfluidic channel on a p-type silicon nanowire (SiNW) array measured by a multiplexed electrical readout. The metal layer sets a constant electrical potential along the microfluidic channel for a given reference electrode voltage regardless of the flow velocity. Without the Ag layer, the magnitude and sign of the surface potential change on the SiNW depends on the flow velocity, width of the microfluidic channel and the device's location inside the microfluidic channel with respect to the reference electrode. Noise analysis of the SiNW array with and without the Ag coating in the fluidic channel shows that noise frequency peaks, resulting from the operation of a piezoelectric micropump, are eliminated using the Ag layer with two reference electrodes located at inlet and outlet. This strategy presents a simple platform to eliminate the streaming potential and can become a powerful tool for nanoscale potentiometric biosensors.

项与 QuantuMDx Group Ltd. 相关的新闻（医药）

2024-04-01

·PRNewswire

Unlocking Precision in Diagnosis: The Rise of Molecular Point-of-Care Solutions

DUBLIN, April 1, 2024 /PRNewswire/ -- The "Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition" report has been added to ResearchAndMarkets.com's offering. Molecular point-of-care (mPOC) diagnostic solutions offer enhanced sensitivity and specificity compared to existing near-patient and rapid tests. They expand diagnostic capabilities in critical care units, physician offices, outpatient clinics, and community health posts, aiming to assess conditions or admit patients accurately. The concept blends the accessibility of point-of-care (POC) testing with the precision of molecular technology. The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition, is a valuable resource for understanding the size and growth potential of the molecular POC market from 2023-2028. mPOC has transitioned from a novel trend to a significant contributor to the market. Instruments from companies like Abbott, BioMerieux, Cepheid, and others play a substantial role in the IVD point-of-care market. Understanding these markets is crucial for assessing the opportunity in point-of-care testing and microbiology IVD. The report provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings. This report provides real-world analysis and modeling for relevant circumstances. Analysts offer insights into near-patient molecular testing using small instruments. The data includes the following information on systems, competitor analysis, and the size and growth of the market: What are the mPOC market opportunities beyond COVID-19? What are the current systems on the market? Who's winning? What's the size of the Molecular Point-of-Care Market: 2023-2028 Geographic Breakout of the Molecular Point-of-Care Market, 2023 (N. America, Europe, APAC, RoW) Segment Breakout of Molecular Point-of-Care Market, 2023 (Respiratory vs. Other) Near Patient Molecular IVD Market: 2023-2028 Near Patient Molecular Market Share by Vendor, 2023 Company Profiles Competitive Analysis Companies covered in this report, in profiles and/or product tables and market developments discussion include: Abbott Laboratories Aidian Akonni Biosystems Anitoa binx health Biocartis BioGX bioMerieux Cepheid Credo Bioscience Cue Health Curetis Curiosity Diagnostics (Bio-Rad) DiaSorin Domus Diagnostics Fluxergy GenMark Diagnostics Genomadix Greiner Bio-One LEX Diagnostics Meridian Bioscience Mesa Biotech MicroGEM Minute Molecular Nanopath QIAGEN QuantuMDx Group Quidel Roche Rover Diagnostics Sekisui Diagnostics T2 Biosystems Key Topics Covered: Chapter 1: Executive Summary Where is Molecular Point-Of-Care in 2024? Molecular Point-Of-Care Market Analysis Market Observations "Near-Patient" Molecular Systems Market Current Trends Molecular Point-Of-Care Diagnostics Defined Usage of Molecular Point-Of-Care Leading MPOC Platforms Trends Chapter 2: Molecular Point-Of-Care Market Development and Trends COVID-19 and Molecular POC CDC Initial Response, Long-Term Situation COVID-19's Unique Challenge Barda Directs Funding to MPOC Regulatory Developments Consortia, Funding, Prizes Deals Advantages and Disadvantages of Molecular Point-Of-Care Justification: The Sensitivity/Specificity Argument New Systems and Menu Expansion Mesa Biotech Strep an Approval Combination Tests Changing Market: Sars-Cov-2, Flu A, Flu B, and RSV STI Continues to be a Growth Area Deals, Investment in MPOC Systems Roche Acquires Lumiradx for Up to $350M Thermo Acquires Mesa Biotech EU Researchers Awarded €3M to Develop POC Molecular Tests Scope Fluidics AST System Sees Investment China as a POC Market Common Tests and Analytes in POC Diagnostics Component Technologies of Molecular Point-Of-Care Diagnostics Microfluidics qPCR Microarrays Isothermal Amplification Test Automation Primers and Probes Detection Next-Generation Sequencing Molecular Diagnostics Real-Time PCR (qPCR) Isothermal Amplification Methods Line Probe Assays Next-Generation Sequencing Applications and Potential Applications for Molecular Point-Of-Care Major Testing Applications for Molecular POC Diagnostics Influenza Reclassification of RIDTs Hospital-Acquired Infections (HAIs) Strep A Respiratory Syncytial Virus (RSV) Emerging Applications Zika Other Respiratory Infections Group B Streptococcus Human Papillomavirus Herpes Simplex Virus Vaginitis Tuberculosis Malaria Other Tropical and Neglected Diseases Cancer European Device Regulations Chapter 3: Market Analysis Molecular Point-Of-Care Market Analysis "Near Patient Molecular" Market Market Share Near Patient Chapter 4: Company Profiles Abbott Laboratories Aidian Akonni Biosystems Binx Health Biocartis Biomerieux Cepheid Credo Diagnostics Biomedical Pte. Ltd. Cue Health Curetis Diasorin Genmark Diagnostics Greiner Bio-One Lucira Health Meridian Bioscience Mesa Biotech Qiagen Quantumdx Group Quidelortho Roche Sekisui Diagnostics T2 Biosystems For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

诊断试剂IPO

2024-03-29

·PRNewswire

World Syndromic Multiplex Panels Market Analysis, Strategies, Trends and Forecasts, 2024-2028: A New Post Pandemic Growth Phase as New Entrants Jockey for Position in a New Diagnostic World

DUBLIN, March 29, 2024 /PRNewswire/ -- The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to ResearchAndMarkets.com's offering. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics. Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home? Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size for five years and even further with a later updated report with next years numbers. Key Topics Covered: 1 Market Guides 1.1 Situation Analysis 1.2 Guide for Executives and Marketing Staff 1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition 2.1 What are Syndromic Multiplex Tests? 2.2 Syndromic Testing - the quiet revolution in diagnostics 2.2.1 Syndromic Testing - more than Panels. 2.3 Market Definition 2.4 Methodology 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 3 Infectious Disease 3.1 Infections - The Big Picture 3.2 The Pathogens 3.2.1 Bacteria 3.2.2 Fungi and Protozoa 3.2.3 Viruses 3.2.4 Prions 3.3 Symptoms and Syndromes 3.3.1 Bacterial or viral 3.3.2 Typical Viral Symptoms 3.3.3 Typical Bacterial Symptoms 3.4 Disease 3.5 Transmission 3.6 Infectious Disease Diagnostics 3.6.1 Microbial culture 3.6.2 Microscopy 3.6.3 Biochemical tests 3.6.4 PCR-based diagnostics 3.6.5 Metagenomic sequencing 3.7 Defining Infections 3.8 Syndromic Infection 4 Industry Overview 4.1 Players in a Dynamic Market 4.1.1 Academic Research Lab 4.1.2 Diagnostic Test Developer 4.1.3 Instrumentation Supplier 4.1.4 Chemical/Reagent Supplier 4.1.5 Pathology Supplier 4.1.6 Independent Clinical Laboratory 4.1.7 Public National/regional Laboratory 4.1.8 Hospital Laboratory 4.1.9 Physicians Office Lab (POLS) 4.1.10 Audit Body 4.1.11 Certification Body 4.2 The Clinical Laboratory Market Segments 4.2.1 Traditional Market Segmentation 4.2.2 Laboratory Focus and Segmentation 4.2.3 Segmenting the Syndromic Testing Market 4.3 Industry Structure 4.3.1 Hospital Testing Share 4.3.2 Economies of Scale 4.3.2.1 Hospital vs. Central Lab 4.3.3 Physician Office Lab's 4.3.4 Physician's and POCT 5 Market Trends 5.1 Factors Driving Growth 5.1.1 Speed of Diagnosis. 5.1.2 Effect of Syndromic Testing on Costs. 5.1.3 Point of Care Advantage. 5.1.4 Accuracy and Diagnostic Risk. 5.1.5 Single Visits. 5.1.6 Improvement in Outcomes. 5.1.7 Impact of the Pandemic. 5.2 Factors Limiting Growth 5.2.1 Lower Prices. 5.2.2 Administration/reimbursement. 5.2.3 Infectious Disease is Declining But.. 5.2.4 Wellness Hurts. 5.2.5 Economic Growth improves Living Standards. 5.2.6 Impact of the Pandemic 5.3 Instrumentation, Automation and Diagnostic Trends 5.3.1 Traditional Automation and Centralization 5.3.2 The New Automation, Decentralization and Point of Care 5.3.3 Instruments Key to Market Share 5.3.4 Bioinformatics Plays a Role 5.3.5 PCR Takes Command 5.3.6 Next Generation Sequencing Fuels a Revolution 5.3.7 NGS Impact on Pricing 5.3.8 Whole Genome Sequencing, A Brave New World 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 5.3.10 Comparing Syndrome and Targeted Testing 5.3.11 The Multiplex Paradigm Shift 5.3.12 The Sepsis Testing Market - Bellwether for Syndromics 5.3.13 The Single Visit and AntiMicrobial Resistance 5.3.14 Syndromics drives POCT adoption. 6 Syndromic Testing Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.1.1 Importance of These Developments 6.1.2 How to Use This Section 6.2 BioMerieux Submits Application for Respiratory, Sore Throat Panel 6.3 Sensible Diagnostics Nabs Award for Respiratory Panel 6.4 Aptitude Medical Systems to Develop At-Home STI Test 6.5 Multiplex Meningitis/Encephalitis Panel Market Expanding 6.6 Burst Dx to Deliver Lab-Accurate ELISA-in-a-Cartridge 6.7 OpGen Seeking Approval for UTI Panel 6.8 Altratech to Enter MDx, POC Space by Supplanting PCR 6.9 BIOFIRE Announces New SPOTFIRE System 6.10 Cambridge Nucleomics to Develop 'Nanobait' Tech 6.11 Takara Bio Developing Multiplex Panels 6.12 Rover Diagnostics Developing Optical Multiplex PCR 6.13 Nanopath Secures Funding to Develop POC Dx 6.14 Genetic Signatures Wins Public Health Wales Contract 6.15 Qiagen Looks to Long-Term Growth 6.16 LexaGene Gets Investment 6.17 Seegene Multiplex COVID-19/Flu/RSV Test Receives Approval 6.18 BforCure to Adapt Rapid PCR Platform for Cancer 6.19 Accelerated Growth for Decentralized Testing 6.20 QuantuMDx Developing Syndromic Panels for European Launch 6.21 Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel 6.22 QuantumDx Gets CE Mark for Rapid PoC PCR System 6.23 Bio-Rad Laboratories, Seegene Partner for MDx Development 6.24 Baebies to Expand Finder Platform 6.25 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio 6.26 Binx Health Targeting Clinics, DTC & OTC With STI Tests 6.27 Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV 6.28 Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic 6.29 MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test 6.30 New Approach Involves Silicon-Based Test for Infectious Disease Screening 6.31 Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test 6.32 Qiagen sees NeuMoDx as Growth Vehicle 6.33 Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround 6.34 Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests 6.35 BioMerieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU 6.36 Infectious Disease Testing Firm Curative Acquires KorvaLabs 6.37 ChromaCode Raises Additional $10M 6.38 COVID-19 Patients Need Syndromic Testing 6.39 GenMark Diagnostics - New Respiratory Panel due in June 6.40 Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark 6.41 Exact Diagnostics launches respiratory panel control 6.42 bioMerieux submits enhanced BIOFIRE BCID2 Panel to FDA 7 Profiles of Key Syndromic Testing Companies 7.1 Abacus Diagnostica 7.2 Abbott Laboratories 7.3 Accelerate Diagnostics 7.4 Ador Diagnostics 7.5 ADT Biotech 7.6 Akonni Biosystems 7.7 Alveo Technologies 7.8 Antelope Dx 7.9 Applied BioCode 7.10 Aureum Diagnostics 7.11 Aus Diagnostics 7.12 Baebies 7.13 Beckman Coulter Diagnostics 7.14 Becton, Dickinson and Company 7.15 Binx Health 7.16 Biocartis 7.17 BioFire Diagnostics (bioMerieux) 7.18 bioMerieux Diagnostics 7.19 Bio-Rad Laboratories, Inc 7.20 Bosch Healthcare Solutions GmbH 7.21 Cepheid (Danaher) 7.22 Credo Diagnostics Biomedical 7.23 Cue Health 7.24 Curetis N.V./Curetis GmbH 7.25 Detect 7.26 Diagenode Diagnostics 7.27 Diasorin S.p.A. 7.28 Domus Diagnostics 7.29 Enzo Biochem 7.30 Eurofins Scientific 7.31 Fluxergy 7.32 Fusion Genomics. 7.33 Genetic Signatures 7.34 GenMark Dx (Roche) 7.35 Grip Molecular Technologies 7.36 Hibergene Diagnostics 7.37 Hologic 7.38 Immunexpress 7.39 Inflammatix 7.40 Invetech 7.41 Janssen Diagnostics 7.42 Karius 7.43 Lexagene 7.44 LightDeck Diagnostics 7.45 Lucira Health 7.46 Luminex Corp (DiaSorin) 7.47 Maxim Biomedical 7.48 Meridian Bioscience 7.49 Mesa Biotech (Thermo Fisher) 7.50 MicroGem 7.51 Millipore Sigma 7.52 Minute Molecular 7.53 Mobidiag (Hologic) 7.54 Molbio Diagnostics 7.55 Nanomix 7.56 Novel Microdevices 7.57 OnsiteGene 7.58 Operon 7.59 Oxford Nanopore Technologies 7.60 Panagene 7.61 Perkin Elmer 7.62 Primerdesign (Novacyt) 7.63 Prominex 7.64 Proof Diagnostics 7.65 Qiagen 7.66 QuantuMDx 7.67 QuidelOrtho 7.68 Roche Molecular Diagnostics 7.69 Saw Diagnostics 7.70 Scope Fluidics 7.71 Seegene 7.72 Siemens Healthineers 7.73 Sona Nanotech 7.74 SpeeDx 7.75 T2 Biosystems 7.76 Talis Biomedical 7.77 Thermo Fisher Scientific Inc. 7.78 Vela Diagnostics 7.79 Veramarx 7.80 Visby Medical 7.81 XCR Diagnostics 8 The Global Market for Syndromic Multiplex Diagnostics 8.1 Global Market Overview by Country 8.2 Global Market by Syndrome - Overview 8.3 Global Market by Place - Overview 8.4 Global Market by Product - Overview 9 Global Syndromic Multiplex Markets - By Syndrome 9.1 Respiratory 9.2 Gastrointestinal 9.3 Blood 9.4 Meningitis/Encephalitis 9.5 Sexually Transmitted Disease 9.6 Other Syndrome 10 Global MDx Infectious Disease Markets - by Place 10.1 Hospital Lab 10.2 Outpatient Lab 10.3 Point of Care 10.4 Other Place 11 Global MDx Infectious Disease Markets - by Product 11.1 Instruments 11.2 Cartridges 11.3 Reagents 11.4 Other Product 12 Appendices 12.1 United States Medicare System: Clinical Laboratory Fees Schedule 12.2 The Most Used IVD Assays 12.3 The Highest Grossing Assays For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

诊断试剂

2024-03-16

·PRNewswire

Global HIV Point of Care (POC) Tests Pipeline Landscape Report 2023: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies

DUBLIN, March 15, 2024 /PRNewswire/ -- The "HIV Point of Care (POC) Tests Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive information about the HIV Point of care (POC) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. HIV Point of care (POC) Tests is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care. POC is typically performed by non-laboratory personnel and the results are used for clinical decision making. POC has a range of complexity and procedures that vary from manual methodologies to automated analyzers. POC devices are often 'handheld' or may be small portable analyzers. Scope Extensive coverage of the HIV Point of care (POC) Tests under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of HIV Point of care (POC) Tests and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment / industry Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of HIV Point of care (POC) Tests under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 HIV Point of care (POC) Tests Overview 3 Products under Development 3.1 HIV Point of care (POC) Tests - Pipeline Products by Stage of Development 3.2 HIV Point of care (POC) Tests - Pipeline Products by Territory 3.3 HIV Point of care (POC) Tests - Pipeline Products by Regulatory Path 3.4 HIV Point of care (POC) Tests - Pipeline Products by Estimated Approval Date 3.5 HIV Point of care (POC) Tests - Ongoing Clinical Trials 4 HIV Point of care (POC) Tests - Pipeline Products under Development by Companies 4.1 HIV Point of care (POC) Tests Companies - Pipeline Products by Stage of Development 4.2 HIV Point of care (POC) Tests - Pipeline Products by Stage of Development 5 HIV Point of care (POC) Tests Companies and Product Overview 6 HIV Point of care (POC) Tests- Recent Developments 6.1 Oct 10, 2023: Trinity Biotech Welcomes the Decision of the High Court of Kenya to Strike Out the Applications to Prevent the Procurement of Trinscreen HIV by the Kenyan Ministry of Health 6.2 Sep 27, 2023: Update on MedMira's Regulatory Path in Canada and the USA 6.3 Jun 14, 2023: Atomo and Newfoundland Sign Agreement for HIV Testing in Europe 6.4 Mar 22, 2023: Trinity Biotech welcomes TrinScreen HIV's inclusion in the New Kenyan HIV Testing Algorithm 6.5 Feb 28, 2023: Significant purchase order for HIV self-tests for Europe 7 Appendix A selection of companies mentioned in this report includes Abbott Rapid Diagnostics GmbH Aldatu Biosciences Inc Altratech Ltd Atomo Diagnostics Ltd Baebies Inc BBB Technologies Inc Beijing Wantai Biological Pharmacy Enterprise Co Ltd Binx Health Inc Bio-AMD Inc Biocartis Group NV BioHelix Corp Bluejay Diagnostics Inc Calypte Biomedical Corporation Centre International de Reference Chantal Biya Cepheid Inc ChipCare Corp CrossLife Technologies Inc Cue Inc Daktari Diagnostics, Inc. Diagnostics For All Inc Diagnostics for the Real World (Europe) Ltd Endeavor Sciences Inc Epinex Diagnostics Inc ERBA Molecular Ltd Fluxergy LLC GAIA Medical Institute LLC genedrive plc Group K Diagnostics Guangzhou Wondfo Biotech Co Ltd HA TECH Pty Ltd HeatFlow Technologies Inc Identifysensors LLC Imperial College London Integrated Diagnostics Inc (Inactive) Intuitive Biosciences Inc Jan Biotech Inc Jinvator Bio Med GmbH Johns Hopkins University Lynntech Inc Maxim Biomedical Inc MedMira Inc Micronics Inc Molbio Diagnostics Pvt Ltd MyMD Pharmaceuticals Inc Nanobiosym Inc Newmark Diagnostics LLC Northwestern University Osel Inc Philmedi Co Ltd Prenetics Ltd QuantuMDx Group Ltd Quidel Corp Radisens Diagnostics Ltd Rheonix Inc Roche Diagnostics International Ltd Sedia Biosciences Corp Sensible Diagnostics Inc Senzo Inc TheoremDx Inc Trinity Biotech Plc University of Connecticut University of Minnesota UrSure Inc Ustar Biotechnologies (Hangzhou) Ltd. Virax Biolabs Group Ltd Wave 80 Biosciences Inc Yaathum Biotech Pvt Ltd For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 项与 QuantuMDx Group Ltd. 相关的药物交易

登录后查看更多信息

100 项与 QuantuMDx Group Ltd. 相关的转化医学

登录后查看更多信息